Skip to main content
. 2016 Jun 24;18(11):1072–1080. doi: 10.1111/dom.12696

Figure 2.

DOM-12696-FIG-0002-b

Insulin dose, body weight, serum triglyceride, and alanine aminotransferase (ALT) change over 26 weeks of treatment. (A) Basal insulin dose. Treatment difference was statistically significant (p < 0.05) from weeks 3–26. (B) Change in body weight. (C) Serum triglyceride. (D) ALT. All data are least squares mean ± standard error. White markers or bars/dashed line = glargine; black markers or bars/solid line = basal insulin peglispro (BIL). Study endpoint indicates last visit completed including 4‐week follow‐up visit. *p < 0.05; **p < 0.01; ***p < 0.001 for differences between treatments.